ArticleCureus2025
Lingual Dystonia Following Thalamic Infarction in a Patient on Methotrexate Therapy for Hidradenitis Suppurativa.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lingual dystonia is a rare form of focal dystonia involving involuntary, repetitive, and often painful muscle contractions of the tongue, which can lead to abnormal tongue posturing or protrusion, dysarthria, and/or dysphagia. Lingual dysotnia can be primary or secondary to various conditions. The thalamus is a key relay center between the motor cortex and basal ganglia, and damage here can disrupt motor signaling pathways, possibly leading to focal dystonia, like lingual dystonia. Methotrexate (MTX) can cause acute to subacute neurological complications, which are linked with high doses of MTX, while chronic MTX neurotoxicity develops more slowly, resulting in persistent focal neurological deficits. We present a 56-year-old male patient on MTX therapy who developed an isolated lingual dystonia as a chronic presentation of a small infarction in the posterolateral thalamus. The finding of thalamic infarction on brain CT and the lack of clinical improvement in dystonia symptoms after prolonged MTX withdrawal from therapy indicate that lingual dystonia could be directly causally related to thalamic insult, while it is less likely that lingual dystonia is a side effect of MTX therapy. This case provides us with new knowledge in determining the etiology of lingual dystonia in the light of thalamic infarction and MTX neurotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.